Lachmann B
Department of Anesthesiology, Erasmus University, Rotterdam, The Netherlands.
Dev Pharmacol Ther. 1989;13(2-4):164-72. doi: 10.1159/000457600.
Before using surfactant preparations in animal experiments or in clinical trials, it is necessary that they fulfil specific in vivo requirements. But conclusive criteria for the effectiveness of a surfactant have not yet been defined. Thus, some standard levels for improvement of lung function, or threshold levels, must be established in standardized animal models with surfactant deficiency. The respiratory distress syndrome model of premature rabbit fetuses is the most sensitive model, followed by the surfactant deficiency model by lung lavage, while the model of viral pneumonia is the least sensitive when testing exogenous surfactant. With a less-effective exogenous surfactat, a small improvement in lung function in the rabbit fetus model and the lung lavage model can be observed, while in the viral pneumonia model almost no improvement occurred. Only a functional effective surfactant fulfilled all our criteria for functional improvement in lung function.
在动物实验或临床试验中使用表面活性剂制剂之前,它们必须满足特定的体内要求。但尚未确定表面活性剂有效性的决定性标准。因此,必须在表面活性剂缺乏的标准化动物模型中建立一些改善肺功能的标准水平或阈值水平。早产兔胎儿的呼吸窘迫综合征模型是最敏感的模型,其次是通过肺灌洗造成的表面活性剂缺乏模型,而在测试外源性表面活性剂时,病毒性肺炎模型最不敏感。使用效果较差的外源性表面活性剂时,在兔胎儿模型和肺灌洗模型中可观察到肺功能有小的改善,而在病毒性肺炎模型中几乎没有改善。只有功能性有效的表面活性剂满足我们对肺功能功能改善的所有标准。